Biomedical Science: Postdoctoral Fellow in Cancer Epigenetics, University of Michigan, Ann Arbor
Ann Arbor, MI
Job posting number: #7062472
Posted: November 25, 2019
Application Deadline: January 25, 2020
Postdoctoral position in biomedical science is available in Prof. Tomasz Cierpicki and Prof. Russell Ryan laboratories, University of Michigan, Ann Arbor, to carry out cancer epigenetic projects focused on studying the effect of small molecules blocking new epigenetic targets and to pursue target validation studies using genetic approaches. The research will focus on evaluation of the activity and the mechanism of action of novel small molecules blocking epigenetic proteins in cancer as well as evaluation of epigenetic and functional effects of perturbing chromatin regulatory proteins in cancer. This position requires the expertise in cell biology and molecular biology techniques, including PCR, qRT-PCR, Western Blotting, co-Immunoprecipitation, ChIP, ChIPSeq, flow cytometry, CRISPR-based “epigenome editing”. Prior work experience with animals such as transgenic mice and xenograft models of cancer would be a plus. Successful candidate will be a part of an interdisciplinary team focused on development and pre-clinical evaluation of novel anti-cancer drug candidates.
Successful candidate will be co-mentored by Drs Cierpicki and Ryan. We offer highly interdisciplinary training in cancer epigenetics that will cover stat-of-the art epigenomic techniques combined with modern tools in chemical biology and drug discovery (e.g. protein-protein interaction inhibitors and PROTACs).
Applicant must have PhD in biology or related field. The candidates must be a first author on at least 2-3 publications. This position requires extensive experience in cell and molecular biology techniques.
Furthermore, excellent oral and written communication skills in English are required as well as the ability to conduct independent scientific investigations.
How to apply
Please submit cover letter, CV, and contact information for 2-3 references combined into one PDF file by e- mail to: email@example.com.
Tomasz Cierpicki, PhD, Associate Professor
Department of Pathology, University of Michigan Ann Arbor, MI, 48109, USA
1. Borkin, D. et al., Cierpicki, T., Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia in vivo, Cancer Cell,
2015, 27 (4), 589-602.
2. He S, et; al., Grembecka J., Menin-MLL inhibitors block oncogenic transformation by MLL fusion proteins in a fusion partner independent
manner. Leukemia. 2016 Feb;30(2):508-13.
3. Ryan RJH, et al: A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas. Cell reports. 2017; 21(3):784-